Macrogenics (FRA:M55) FCF Margin % : -220.12% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Macrogenics's Free Cash Flow for the three months ended in Dec. 2024 was €-37.3 Mil. Macrogenics's Revenue for the three months ended in Dec. 2024 was €16.9 Mil. Therefore, Macrogenics's FCF Margin % for the quarter that ended in Dec. 2024 was -220.12%.

As of today, Macrogenics's current FCF Yield % is -90.67%.

The historical rank and industry rank for Macrogenics's FCF Margin % or its related term are showing as below:

FRA:M55' s FCF Margin % Range Over the Past 10 Years
Min: -303.85 Med: -90.44 Max: -9.64
Current: -51.24

During the past 13 years, the highest FCF Margin % of Macrogenics was -9.64%. The lowest was -303.85%. And the median was -90.44%.

FRA:M55's FCF Margin % is ranked better than
60.12% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs FRA:M55: -51.24

Macrogenics FCF Margin % Historical Data

The historical data trend for Macrogenics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics FCF Margin % Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-120.50

-198.34

-60.38

-139.82

-48.59

Macrogenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-312.73	-517.36	-421.63	53.81	-220.12

Competitive Comparison of Macrogenics's FCF Margin %

For the Biotechnology subindustry, Macrogenics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Macrogenics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Macrogenics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Macrogenics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-68.835	/	141.664
	=	-48.59 %

Macrogenics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-37.271	/	16.932
	=	-220.12 %

Macrogenics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Macrogenics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Headlines

No Headlines